Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024GlobeNewsWire • 04/16/24
Genmab Slumps On Its $1.8 Billion Takeover Of Cancer Specialist ProfoundBioInvestors Business Daily • 04/03/24
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBioBusiness Wire • 04/03/24
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated personsGlobeNewsWire • 03/13/24
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in GenmabGlobeNewsWire • 03/13/24
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular LymphomaBusiness Wire • 02/27/24
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in GenmabGlobeNewsWire • 02/23/24
Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical CancerBusiness Wire • 02/02/24